A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state

双特异性抗体 抗体 凝结 免疫球蛋白轻链 体外 化学 医学 药理学 免疫学 内科学 单克隆抗体 生物化学
作者
Yuri Teranishi-Ikawa,Tetsuhiro Soeda,Hikaru Koga,Kazuki Yamaguchi,Kazúo Kato,Keiko Esaki,Kentaro Asanuma,Miho Funaki,Mina Ichiki,Yuri Ikuta,Shunsuke Ito,Eri Joyashiki,Shunichiro Komatsu,Atsushi Muto,K. Nishimura,Momoko Okuda,Hisakazu Sanada,Motohiko Sato,Norihito Shibahara,Tetsuya Wakabayashi,Koji Yamaguchi,Akiko Matsusaki,Zenjiro Sampei,Hirotake Shiraiwa,Hiroko Konishi,Yojiro Kawabe,Kunihiro Hattori,Takio Kitazawa,Tomoyuki Igawa
标识
DOI:10.1101/2022.12.19.520692
摘要

Abstract Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies suggest that a small proportion of PwHA still experiences bleeds. Additionally, non-clinical studies indicate that the maximum cofactor activity of emicizumab is lower than international standard activity (100 IU/dL of FVIII). An increased cofactor activity BsAb would benefit such patients. Here, we report NXT007, a BsAb binding FIXa and FX developed through further engineering of emicizumab. Emicizumab has a common light chain, but through advances in antibody engineering, we were able to create a more potent BsAb with two new non-common light chains. After extensive optimization of the heavy and light chains, the resulting BsAb, NXT007, exerted in vitro thrombin generation (TG) activity in hemophilia A plasma equivalent to 100 IU/dL of FVIII when triggered by tissue factor. NXT007 demonstrated potent hemostatic activity in an acquired hemophilia A model in non-human primates at a much lower dosage than emicizumab, consistent with an around 30-fold dose shift in the in vitro TG activity between NXT007 and emicizumab. Moreover, together with Fc engineering that enhanced FcRn binding and reduced in vivo clearance, we demonstrate that NXT007 could be effective at a much lower dosage with a longer dosing interval compared to emicizumab. These non-clinical results suggest that NXT007 could maintain a non-hemophilic range of coagulation potential in PwHA and provides a rationale for its clinical testing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助Desire采纳,获得10
刚刚
量子星尘发布了新的文献求助10
3秒前
风信子完成签到,获得积分10
3秒前
小熊完成签到 ,获得积分10
5秒前
9秒前
shu完成签到,获得积分10
9秒前
9秒前
勤奋的毛豆完成签到,获得积分10
12秒前
行者无疆完成签到,获得积分10
12秒前
13秒前
Jackylee完成签到,获得积分10
13秒前
careyzhou发布了新的文献求助10
14秒前
舒心之云完成签到,获得积分10
16秒前
Desire发布了新的文献求助10
16秒前
独自受罪完成签到 ,获得积分10
17秒前
甘蓝型油菜完成签到,获得积分10
18秒前
Distance发布了新的文献求助10
19秒前
大橙子发布了新的文献求助10
20秒前
毛哥看文献完成签到 ,获得积分10
20秒前
Desire完成签到,获得积分10
22秒前
AiQi完成签到 ,获得积分10
23秒前
月月鸟完成签到 ,获得积分10
24秒前
陈永伟完成签到,获得积分10
26秒前
传奇3应助qq采纳,获得10
26秒前
feihua1完成签到 ,获得积分10
27秒前
大轩完成签到 ,获得积分10
28秒前
miemie66完成签到,获得积分10
29秒前
30秒前
Sun1c7完成签到,获得积分10
30秒前
大仁哥完成签到,获得积分10
30秒前
qqy完成签到,获得积分10
31秒前
失眠的香菇完成签到 ,获得积分10
33秒前
机灵的笼包完成签到,获得积分10
33秒前
兔子发布了新的文献求助10
34秒前
ohwhale完成签到 ,获得积分10
35秒前
chaotianjiao完成签到 ,获得积分10
36秒前
阳光的耳机完成签到,获得积分10
37秒前
K珑完成签到,获得积分10
37秒前
Solar energy完成签到,获得积分10
39秒前
鲤鱼青雪发布了新的文献求助10
40秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022